Compare Agilent Technologies Inc (A) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Tempus AI — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Tempus AI trades at $55.55 (market cap $9.93B). The key difference: Agilent Technologies Inc is far larger — about 4.2× Tempus AI's market cap, and Agilent Technologies Inc pays a 0.69% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| A | TEM | |
|---|---|---|
Market Cap | $42.00B | $9.93B |
Sector | Health | Broad Market / Factor |
52-Week High | $157.20 | $103.25 |
52-Week Low | $110.24 | $41.55 |
Enterprise Value | $43.55B | $10.56B |
Dividend Yield | 0.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Tempus AI (TEM) trades at $52.05, up 12.86% in 24 hours, reflecting strong momentum after Q2 2026 earnings beat revenue estimates and raised 2026 sales guidance. The stock is technically bullish with moving averages supporting upside, while fundamentals show revenue growth to $1.4 billion in 2026 but persistent net losses. Recent news highlights expansion through the Personalis acquisition and AI-driven precision medicine advancements.
Outlook: Growth prospects are robust with AI adoption in healthcare and strategic deals, but high valuation ratios and negative profitability pose risks. Analysts are bullish with a $61.57 consensus target, though cash burn and competitive pressures require monitoring for sustained investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
